Deinove appoints business development director

Michael Krel will form industrial alliances with leading chemicals companies

Deinove, a French specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, has appointed Michael Krel to the newly created post of executive vice president, business development.

Krel was previously business development manager at Metabolic Explorer, a green chemistry company specialising in the development of fermentation processes for commodity chemicals.

Deinove chief executive Jacques Biton said Krel’s main role will be to form collaborations and licensing deals with biofuels and chemicals companies worldwide.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Manufacturing

LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations

Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Subscribe now